

10/560513

37 CFR PCT/PTO 13 DEC 2005

Attorney Docket No. VB60298

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP2004/006426	14 June 2004	16 June 2003

TITLE OF INVENTION

POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZA B
SACCHARIDE VACCINES

APPLICANT(S) FOR DO/US

Nathalie Marie-Josephe GARCON, Dominique LEMOINE, Florence Emilie Jeanne Francoise
WAUTERS


FILING OF AN INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

A copy of the International Search Report, which issued on International Application No. PCT/EP2004/006426 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

Copies of references not listed on the International Search Report are enclosed.

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Jeffrey A. Sutton
Attorney for Applicants
Registration No. 34,028

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6316
Facsimile (610) 270-5090
N:\JAS\PTO\VB60298\Natl Stage Transmittal.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. VB60298	INTERNATIONAL APPLICATION NO. PCT/EP2004/006426
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Garcon et al.	
		FILING DATE Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
		WO 98/17310	4/30/98	PCT			
		WO 02/00249	1/3/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Gupta et al., "Biodegradable Polymer Microspheres as Vaccine Adjuvants and Delivery Systems". <i>Developments in Biological Standardization</i> , <u>92</u> : 63-78 (1998).
	Boehm-Gerard et al., "On Technological and Immunological Benefits of Multivalent Single-Injection Microsphere Vaccines". <i>Pharmaceutical Research</i> , <u>19</u> (9): 1330-1336 (2002).
	Raghuvanshi et al., "Improved Immune Response from Biodegradable Polymer Particles Entrapping Tetanus Toxoid by use of Different Immunization Protocol and Adjuvants". <i>Int'l. J. Pharmaceutics</i> , <u>245</u> (1-2): 109-121 (2002).
	Peyre et al., "An Experimental Divalent Vaccine Based on Biodegradable Microspheres induces Protective Immunity Against Tetanus and Diphtheria". <i>J. Pharm. Sci.</i> , <u>92</u> (5): 857-966 (2003).
	Gupta et al., "Evaluation of a Guinea Pig Model to Assess Interference in the Immunogenicity of Different Components of a Combination Vaccine Comprising Diphtheria, Tetanus and Acellular Pertussis (DTaP) Vaccine and Haemophilus Influenzae Type B Capsular Polysaccharide Conjugate Vaccine". <i>Biologicals</i> , <u>27</u> (2): 167-176 (1999).
	Richard et al., "Production and Mass Transfer Characteristics of Non-Newtonian Biopolymers for Biomedical Applications". <i>CRC Critical Rev. in Biotechnol.</i> , <u>22</u> (4): 355-374 (2002).
	Nichol et al., "Poly-L-glutamate, an Anionic Polymer, Enhances Transgene Expression for Plasmids Delivered by Intramuscular Injection with in vivo Electroporation". <i>Gene Ther.</i> , <u>9</u> (20): 1351-1358 (2002).
	Milas et al., "Poly(L-glutamic acid)-Paclitaxel Conjugate is a Potent Enhancer of Tumor Radiocurability". <i>Int'l. J. Radiation Oncol. Biol. Phys.</i> , <u>55</u> (3): 707-712 (2003).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/560513
USPTO Rec'd PCT/PTO 13 DEC 2005

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. VB60298	INTERNATIONAL APPLICATION NO. PCT/EP2004/006426
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Garcon et al.	
		FILING DATE Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Yang et al., "Poly(glutamic acid) Poly(ethylene glycol) Hydrogels Prepared by Photoinduced Polymerization: Synthesis, Characterization, and Preliminary Release Studies of Protein Drugs". <i>J. Biomed. Materials Res.</i> , <u>62</u> (1): 14-21 (2002).
	Diwan et al., "Enhancement of Immune Responses by Co-Delivery of a CpG Oligodeoxynucleotide and Tetanus Toxoid in Biodegradable Nanospheres". <i>J. Controlled Rel.</i> , <u>85</u> (1-3): 247-262 (2002).
	Sanchez et al., "Formulation Strategies for the Stabilization of Tetanus Toxoid in Poly(lactide-co-glycolide) Microspheres". <i>Int'l.J. Pharmaceutics.</i> , <u>185</u> (2): 255-266 (1999).
	Esparza et al., "Parameters Affecting the Immunogenicity of Microencapsulated Tetanus Toxoid". <i>Vaccine</i> , <u>10</u> (10): 714-719 (1992).
	GlaxoSmithKline NZ Ltd. "Datasheet – Hiberix". New Zealand and Medical Devices Safety Authority, 'Online! 2002, XP002306401.
	Jiang et al., "Stabilization of a Model Formalinized Protein Antigen Encapsulated in Poly(lactide-co-glycolide)-based Microspheres". <i>J. Pharm. Sci.</i> , <u>90</u> (10): 1558-1569 (2001).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.